Compare Nu Holdings Ltd (NU) vs Novavax Inc (NVAX) Price & Performance

NU Holdings (NU) trades at $15.58, down 0.51% on the day, with strong fundamental momentum despite recent volatility. The stock shows bullish technical signals with moving averages supporting upward trends, while oscillators indicate some near-term pressure. Revenue growth has accelerated from $3.0B in 2022 to $10.6B in 2025, with net income turning positive and reaching $2.9B. Recent news highlights acquisition speculation and Goldman Sachs' bullish stance, though the company denied Monzo deal talks.

The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target offering 6% upside. Key opportunities include expanding Latin American digital banking penetration and strong profitability metrics (27.4% net margin). Risks include credit quality concerns from rising delinquencies and competitive pressures in fintech. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.